FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(h) of the Investment Company Act of 1940	
1. Name and Addr Ray Anne M	ess of Reporting Pers <mark>Íarie</mark>	on <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol Vera Bradley, Inc. [ VRA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title X Other (specify
(Last) (First) C/O VERA BRADLEY, INC. 12420 STONEBRIDGE ROAI		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/23/2019	below) A below)  Member of a 10% owner group
(Street) ROANOKE	IN (State)	46783 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person

ROANOKE IN 46/83		Form filed by More than One Reporting Person								eporting
(City) (State) (Zip)	Non Dominativa	Convition An		4 D:	anacad of	or Do	noficially	v Oversod		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date,	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/23/2019		S		3,276(1)	D	\$9.37 <sup>(2)</sup>	172,908	I	By Anne- Marie Ray Revocable Trust
Common Stock	01/24/2019		S		3,276(1)	D	\$9.24(2)	169,632	I	By Anne- Marie Ray Revocable Trust
Common Stock	01/23/2019		S		10,913(1)	D	\$9.38 <sup>(3)</sup>	163,722	I	By Michael Ray 2009 Grantor Retained Annuity Trust
Common Stock	01/24/2019		S		10,913 <sup>(1)</sup>	D	\$9.25 <sup>(3)</sup>	152,809	I	By Michael Ray 2009 Grantor Retained Annuity Trust
Common Stock								2,810,469(4)	I	By Barbara B. Baekgaard 2009 Grantor Retained Annuity Trust
Common Stock								411,003	I	By Anne- Marie Ray 2017 Grantor Retained Annuity Trust #1

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Ta Date (Month/Day/Year)	Iffe Tremberiva Execution Date, if any (e.g., p (Month/Day/Year)	utsiegalls,	tiesumeeil of Waltiants, Securities Acquired (A) or Disposed of (D)	ifentesisisisisisisis Expration Date Quximusy/Ranvertib	Dr Beneficiall Amount of Amount of Besagustities) Underlying Derivative Security (Instr. 3 and 4)	Derivative	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	(Instr. 3, 4 and 5) 5. Number of Derivative Securities Acquired (A) or (D) Disposed	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date	7. Title and Amount Annount Securities Underlyingmber Derivative Sitterity Situates 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Explanation of Responses:					of (D)		,		Transaction(s)		

1. The sales reported in this Form 4 were effected under a Rule 10b5-1 trading plan adough 50 April 6, 2018.

## Remarks:

/s/ Anne-Marie Ray 01/24/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> The prices reported are weighted average prices. The shares sold on January 23, 2019 were sold in multiple transactions at prices ranging from \$9.29 to \$9.49, inclusive, and the shares sold on January 24, 2019 were sold in multiple transactions at prices ranging from \$9.16 to \$9.31, inclusive. The reporting person undertakes to provide the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth of this footnote.

3. The prices reported are weighted average prices. The shares sold on January 23, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices ranging from \$9.29 to \$9.52, inclusive, and the shares sold on January 24, 2019 were sold in patient transactions at prices rangi

<sup>2019</sup> were sold in multiple transactions at prices ranging from \$9.16 to \$506 in "indusive" (Ape reporting previous that are only in the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

<sup>4.</sup> The reporting person disclaims beneficial ownership of these shares, except to the extent of the reporting person's pecuniary interest therein.